The DOI matches its Crossref record.
Emergence of azole drug resistance in Candida species from HIV-infected patients receivingprolonged fluconazole therapy for oral candidosis
Abstract
We examined the effect of different fluconazole treatment regimens on the emergence of azole drug resistance among Candida species recovered from the mouths of 54 HIV-infected individuals. Patients were assigned to one of three treatment groups depending on their history of oral candidosis and fluconazole use. Mouthwashes obtained at regular intervals were cultured and isolates identified using standard methods. Antifungal broth micro-dilution tests were performed to determine IC30s of fluconazole and ketoconazole. Sixty-four Candida albicans isolates from 20 patients with no evidence of oral candidosis who had not received fluconazole all had IC30s of < or = 4 mg/L. Thirty-four (83%) of 41 C. albicans isolates from ten patients receiving intermittent, short-term fluconazole treatment for oral candidosis had IC30s of < or = 4 mg/L, but only two isolates (5%) had IC30s > or = 64 mg/L. In contrast, 26 (40%) of 65 C. albicans isolates from 15 patients given long-term fluconazole (50-200 mg/day or 150 mg/week) were classified as resistant having IC30s of fluconazole of > or = 64 mg/L. Ten of these 26 fluconazole-resistant isolates were susceptible to ketoconazole with IC30s of < or = 4 mg/L suggesting azole drug cross-resistance is not inevitable. Tests on multiple colonies from individual isolation plates showed that it was not unusual to obtain differing IC30 values, indicating that a sweep inoculum is essential if resistance is to be detected. Nine (60%) of the 15 patients given long-term fluconazole harboured isolates of C. albicans that were resistant to fluconazole at some time during the study period. All had low CD4 counts and were approaching the final stage of their illness. Three patients on long-term treatment had resistant organisms at the outset of the study; in the remainder, resistant strains emerged during the study period. In six of the nine cases, emergence of resistance in vitro correlated with persistent clinical signs of oral infection. Thirty-six isolates of Candida species other than C. albicans were also recovered from patients receiving long-term fluconazole and 29 (81%) of these had IC30s of > or = 64 mg/L. Our experience with C. albicans in patients with HIV infection, suggests that the long-term azole drug use may be an important factor in the development of fluconazole resistance as such resistance was rare and transient in patients on intermittent short-term treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Tackling the emerging threat of antifungal resistance to human health
Fisher, M. C., Alastruey-Izquierdo, A., Berman, J., Bicanic, T., Bignell, E. M., Bowyer, P., Bromley, M., Brüggemann, R., Garber, G., Cornely, O. A., et al. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00720-1 · Cited by 1,179
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Antifungal agents: chemotherapeutic targets and immunologic strategies
Georgopapadakou, N. H., & Walsh, T. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.279 · Cited by 498
Antifungal photodynamic therapy
Donnelly, R. F., McCarron, P. A., & Tunney, M. M. (2008) · Microbiological Research · doi:10.1016/j.micres.2007.08.001 · Cited by 453
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2300 · Cited by 402
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Anti-microbial photodynamic therapy: useful in the future?
Maisch, T. (2007) · Lasers in Medical Science · doi:10.1007/s10103-006-0409-7 · Cited by 356
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
ANTIMICROBIAL RESISTANCE IN INTENSIVE CARE UNITS
Fridkin, S. K., & Gaynes, R. P. (1999) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70143-x · Cited by 325
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Al-Tel, T. H., Al-Qawasmeh, R. A., & Zaarour, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.051 · Cited by 252
Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candidaalbicans strains
Maesaki, S., Marichal, P., Bossche, H. V., Sanglard, D., & Kohno, S. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.1.27 · Cited by 162
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
Photosensitization of different Candida species by low power laser light
de Souza, S. C., Junqueira, J. C., Balducci, I., Koga-Ito, C. Y., Munin, E., & Jorge, A. O. C. (2006) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2005.12.002 · Cited by 147
Formation of Azole-Resistant Candida albicans by Mutation of Sterol 14-Demethylase P450
Asai, K., Tsuchimori, N., Okonogi, K., Perfect, J. R., Gotoh, O., & Yoshida, Y. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1163 · Cited by 102
Chin, N. X., Weitzman, I., & Della-Latta, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.850 · Cited by 101
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., Hilsenbeck, S. G., & Patterson, T. F. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00137-5 · Cited by 67
Chen, L., Zhang, L., Xie, Y., Wang, Y., Tian, X., Fang, W., Xue, X., & Wang, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115007 · Cited by 63
Vazquez, J. A., Peng, G., Sobel, J. D., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. O. A. (2001) · Clinical Infectious Diseases · doi:10.1086/322641 · Cited by 57
Vazquez, J. A., Sobel, J. D., Peng, G., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. I. A. (1999) · Clinical Infectious Diseases · doi:10.1086/514746 · Cited by 51
“[26] reported that six of 22 patients who receiving long-term fluconazole harbored two species on the same or different occasions.”
BackgroundMasiá Canuto, M., Gutiérrez Rodero, F., Ortiz de la Tabla Ducasse, V., Hernández Aguado, I., Martín González, C., Sánchez Sevillano, A., & Martín Hidalgo, A. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000323 · Cited by 46
Metadata
- Authors
- Johnson, E. M., Warnock, D. W., Luker, J., Porter, S. R., & Scully, C.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1995
- Volume
- 35
- Issue
- 1
- Pages
- 103-114
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2031686290
- Cited by
- 259
- References
- 0
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.